Daniela Pietrasanta
Overview
Explore the profile of Daniela Pietrasanta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tavarozzi R, Zacchi G, Pietrasanta D, Catania G, Castellino A, Monaco F, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001657
We are currently witnessing a dramatic shift in our approach to the treatment of B-cell non-Hodgkin lymphoma (B-NHL). In the evolving clinical landscape, novel treatments for this clinically heterogeneous disease...
2.
Visentin A, Mauro F, Scarfo L, Gentile M, Farina L, Reda G, et al.
Am J Hematol
. 2023 Jun;
98(9):E237-E240.
PMID: 37382471
No abstract available.
3.
Catania G, Tavarozzi R, Pini G, Borra T, Gandolfo C, Zacchi G, et al.
J Basic Clin Physiol Pharmacol
. 2023 Apr;
34(3):401-404.
PMID: 37040263
Objectives: The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. "Accelerated" chronic lymphocytic...
4.
Mauro F, Della Starza I, Messina M, Reda G, Trentin L, Coscia M, et al.
Haematologica
. 2023 Jan;
108(8):2091-2100.
PMID: 36632738
The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of front-line, fixed-duration venetoclax and rituximab (VenR) in combination in young (≤65 years), fit patients with chronic lymphocytic...
5.
Levi S, Bronstein Y, Goldschmidt N, Morabito F, Ziv-Baran T, Del Poeta G, et al.
Am J Hematol
. 2022 Nov;
98(2):E24-E27.
PMID: 36349541
No abstract available.
6.
Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, et al.
Blood Adv
. 2022 Jul;
6(13):3875-3878.
PMID: 35789375
No abstract available.
7.
Mauro F, Paoloni F, Molica S, Reda G, Trentin L, Sportoletti P, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008372
The GIMEMA group investigated the efficacy, safety, and rates of discontinuations of the ibrutinib and rituximab regimen in previously untreated and unfit patients with chronic lymphocytic leukemia (CLL). Treatment consisted...
8.
Visentin A, Mauro F, Cibien F, Vitale C, Reda G, Fresa A, et al.
Am J Hematol
. 2021 Dec;
97(3):E95-E99.
PMID: 34904743
No abstract available.
9.
Cuneo A, Rigolin G, Coscia M, Quaresmini G, Scarfo L, Mauro F, et al.
Hematol Oncol
. 2021 Jul;
39(4):570-574.
PMID: 34258787
No abstract available.
10.
Morabito F, Del Poeta G, Mauro F, Reda G, Sportoletti P, Laurenti L, et al.
Am J Hematol
. 2021 May;
96(8):E306-E310.
PMID: 33989438
No abstract available.